Influence of model-predicted rivaroxaban exposure and patient characteristics on efficacy and safety outcomes in patients with acute coronary syndrome.
Acute Coronary Syndrome
/ blood
Aged
Brain Ischemia
/ mortality
Clinical Decision-Making
Clinical Trials, Phase III as Topic
Dose-Response Relationship, Drug
Drug Dosage Calculations
Drug Monitoring
Factor Xa Inhibitors
/ administration & dosage
Female
Hemorrhage
/ chemically induced
Humans
Male
Middle Aged
Models, Biological
Myocardial Infarction
/ mortality
Randomized Controlled Trials as Topic
Risk Assessment
Risk Factors
Rivaroxaban
/ administration & dosage
Stroke
/ mortality
Treatment Outcome
acute coronary syndromes
bleeding
exposure–response analysis
monitoring
population pharmacokinetics
rivaroxaban
Journal
Therapeutic advances in cardiovascular disease
ISSN: 1753-9455
Titre abrégé: Ther Adv Cardiovasc Dis
Pays: England
ID NLM: 101316343
Informations de publication
Date de publication:
Historique:
entrez:
1
8
2019
pubmed:
1
8
2019
medline:
14
8
2019
Statut:
ppublish
Résumé
This analysis aimed to evaluate the impact of rivaroxaban exposure and patient characteristics on efficacy and safety outcomes in patients with acute coronary syndrome (ACS) and to determine whether therapeutic drug monitoring might provide additional information regarding rivaroxaban dose, beyond what patient characteristics provide. A For the incidence of myocardial infarction (MI), ischemic stroke, or nonhemorrhagic cardiovascular death, hazard ratios (HRs) for steady-state maximum plasma concentration (C The shallow slopes of the exposure-response relationships and the lack of a clear therapeutic window render it unlikely that therapeutic drug monitoring in patients with ACS would provide additional information regarding rivaroxaban dose beyond that provided by patient characteristics.
Sections du résumé
BACKGROUND
BACKGROUND
This analysis aimed to evaluate the impact of rivaroxaban exposure and patient characteristics on efficacy and safety outcomes in patients with acute coronary syndrome (ACS) and to determine whether therapeutic drug monitoring might provide additional information regarding rivaroxaban dose, beyond what patient characteristics provide.
METHODS
METHODS
A
RESULTS
RESULTS
For the incidence of myocardial infarction (MI), ischemic stroke, or nonhemorrhagic cardiovascular death, hazard ratios (HRs) for steady-state maximum plasma concentration (C
CONCLUSIONS
CONCLUSIONS
The shallow slopes of the exposure-response relationships and the lack of a clear therapeutic window render it unlikely that therapeutic drug monitoring in patients with ACS would provide additional information regarding rivaroxaban dose beyond that provided by patient characteristics.
Identifiants
pubmed: 31364490
doi: 10.1177/1753944719863641
pmc: PMC6669848
doi:
Substances chimiques
Factor Xa Inhibitors
0
Rivaroxaban
9NDF7JZ4M3
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1753944719863641Références
Adv Ren Replace Ther. 2000 Jan;7(1):11-21
pubmed: 10672914
JAMA. 2000 Aug 16;284(7):835-42
pubmed: 10938172
Circulation. 2000 Oct 24;102(17):2031-7
pubmed: 11044416
Drug Metab Dispos. 2009 May;37(5):1056-64
pubmed: 19196845
Lancet. 2009 Jul 4;374(9683):29-38
pubmed: 19539361
Am Heart J. 2011 May;161(5):815-821.e6
pubmed: 21570509
N Engl J Med. 2012 Jan 5;366(1):9-19
pubmed: 22077192
Int J Clin Pharmacol Ther. 2013 Jul;51(7):549-61
pubmed: 23458226
Thromb J. 2013 Jul 03;11(1):11
pubmed: 23822763
Clin Pharmacokinet. 2014 Jan;53(1):1-16
pubmed: 23999929
BMJ Open. 2014 Feb 21;4(2):e004425
pubmed: 24561498
Eur J Clin Pharmacol. 2014 Nov;70(11):1339-51
pubmed: 25168620
Lancet. 2015 Jun 6;385(9984):2288-95
pubmed: 25769361
CPT Pharmacometrics Syst Pharmacol. 2016 Apr;5(4):222-32
pubmed: 27299709
CPT Pharmacometrics Syst Pharmacol. 2017 May;6(5):340-349
pubmed: 28547774
CPT Pharmacometrics Syst Pharmacol. 2018 May;7(5):309-320
pubmed: 29660785